Oxymetazoline
| 證據等級: L5 | 預測適應症: 3 個 |
目錄
Oxymetazoline: From Nasal Congestion to Nasal Cavity Disease
One-Sentence Summary
Oxymetazoline is a topical α1/α2-adrenergic agonist historically used as an over-the-counter nasal decongestant. The TxGNN model predicts it may be effective more broadly for Nasal Cavity Disease, a prediction that is mechanistically expected rather than novel, with 17 clinical trials and 5 publications identified in the evidence pack, though only a minority directly test oxymetazoline itself.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Nasal congestion (OTC nasal decongestant use — not currently SAHPRA-registered, see Market Status) |
| Predicted New Indication | Nasal Cavity Disease |
| TxGNN Prediction Score | 99.96% |
| Evidence Level | L3 |
| South Africa Market Status | Not Marketed |
| Number of SAHPRA Registrations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Oxymetazoline is an α1/α2-adrenergic receptor agonist that acts directly on the vascular smooth muscle of the nasal mucosa, causing vasoconstriction and reducing mucosal swelling. This is the drug’s most direct and well-established pharmacological pathway — it is, in fact, the same mechanism underlying its established OTC nasal decongestant use.
Because “Nasal Cavity Disease” is a broad diagnostic category encompassing nasal congestion, obstruction, and related mucosal pathology, this prediction largely reflects the drug’s known mechanism rather than a genuinely novel repurposing hypothesis. The mechanistic link is strong precisely because the original and predicted indications sit on the same pharmacological axis (nasal mucosal vasoconstriction).
Detailed, drug-specific mechanism-of-action documentation (DrugBank MOA field) was not available in this evidence pack (data gap DG002); the mechanistic description above is derived from the model’s own repurposing rationale rather than a formal DrugBank MOA record.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT03228914 | Phase 4 | Completed | 20 | Compared preoperative topical 0.05% oxymetazoline vs. 1:1000 epinephrine on blood loss and surgical field visualization before endoscopic sinus surgery — direct oxymetazoline trial |
| NCT00562120 | Phase 2 | Completed | 21 | Double-blind crossover study of an H3 receptor antagonist on nasal congestion after allergen challenge, using acoustic rhinometry as endpoint |
| NCT00147940 | Phase 4 | Terminated | 20 | Correlated nasal volume/cross-sectional area with nasalance scores via acoustic rhinometry (decongestant commonly used as pre-treatment in this methodology) |
| NCT01411969 | N/A | Completed | 16 | Examined external nasal dilator strips after decongestion with 0.05% oxymetazoline aerosol spray |
| NCT03620513 | Phase 4 | Completed | 160 | Compared topical anesthesia vs. decongestant vs. combination for reducing pain/discomfort during fiberoptic nasal pharyngoscopy |
| NCT03962634 | Phase 2 | Terminated | 3 | Kovanaze (tetracaine/oxymetazoline nasal mist) vs. articaine injection for maxillary tooth pulpal anesthesia |
| NCT04104789 | Phase 2 | Withdrawn | 0 | Same design as NCT03962634 (Kovanaze vs. articaine), withdrawn before enrollment |
| NCT03380715 | N/A | Completed | 106 | Co-phenylcaine nasal spray vs. nasal nebulization prior to rigid nasoendoscopy — decongestant class comparator, not oxymetazoline itself |
| NCT06443255 | Phase 3 | Completed | 16 | Crossover comparison of cocaine, lidocaine/xylometazoline, and saline for intranasal analgesia before nasotracheal intubation — related decongestant (xylometazoline), not oxymetazoline |
| NCT06457100 | Phase 1/2 | Active, not recruiting | 60 | Perioperative esmolol vs. lidocaine infusion during functional endoscopic sinus surgery, context involves epinephrine-based nasal vasoconstriction |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 9929658 | 1998 | Cohort/Observational | Annals of the New York Academy of Sciences | Assessed olfactory function and nasal volume (acoustic rhinometry) during acute rhinitis |
| 25496205 | 2015 | Cohort | Journal of Plastic Surgery and Hand Surgery | Evaluated nasal patency by acoustic rhinometry after cleft lip/palate repair |
| 8615587 | 1996 | Animal/Preclinical | Annals of Otology, Rhinology & Laryngology | Direct oxymetazoline study — evaluated effect of oxymetazoline nose drops on early local tissue defense in experimental rabbit sinusitis |
| 38024464 | 2023 | Case Report | Global Pediatric Health | Case report of rhinoscleroma (nasal cavity granulomatous disease) in a 9-year-old; no oxymetazoline data |
| 28490409 | 2017 | Case Series | American Journal of Rhinology & Allergy | Endoscopic coblation treatment of nasal telangiectasias in hereditary hemorrhagic telangiectasia; no oxymetazoline data |
South Africa Market Information
Oxymetazoline currently has no SAHPRA registrations on file in this evidence pack (0 licenses, market status: Not Marketed). No registered product, dosage form, or approved indication text is available to summarize.
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
Note: Key warnings, contraindications, and drug–drug interaction data were flagged as a Blocking data gap (DG001) in this evidence pack — the DDI query itself returned no results (not_found). This gap must be resolved before any formal safety evaluation (S1) can proceed.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: The predicted association between oxymetazoline and nasal cavity disease is mechanistically well-founded — it reflects the drug’s established α-adrenergic vasoconstrictive action rather than a novel hypothesis — but direct clinical evidence testing oxymetazoline against a defined “nasal cavity disease” endpoint remains limited (only 1 trial, NCT03228914, is a direct Phase 4 oxymetazoline comparison). Combined with the absence of SAHPRA registration and a Blocking safety data gap (DG001), this supports guarded rather than unconditional progression.
To proceed, the following is needed:
- TFDA/SAHPRA-approved Professional Information (PI) — warnings, precautions, and contraindications (DG001, Blocking)
- Confirmed DrugBank mechanism-of-action record (DG002, High)
- Clarification of SAHPRA registration pathway, since the drug is currently not marketed in South Africa
- A formal drug–drug interaction (DDI) search, since the current query returned no results
- Protocol-level confirmation of which “nasal cavity disease” subtype(s) the predicted indication targets, to align with the single directly relevant Phase 4 trial identified
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.